Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful closing of an oversubscribed $93.5 million Series A financing. This…
Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company pioneering in vivo therapies to engineer the hematopoietic system, has announced that the U.S. Food and Drug Administration (FDA) has…
Alto Neuroscience Reports Positive Interim Analysis Outcome for ALTO-300 Phase 2b Trial in Major Depressive Disorder Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders, has announced the favorable outcome of…
Abcuro Secures $200M Series C to Advance Inclusion Body Myositis Drug Abcuro, Inc., a clinical-stage biotechnology company focused on developing innovative therapies to treat autoimmune diseases and cancer by precisely modulating cytotoxic T cells, has successfully closed a $200 million…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in Molecular Pharmaceutics, highlights the platform’s unique ability to improve drug…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced the presentation of novel data on long-term prophylaxis (LTP) and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting, held in Waimea, HI, from February 9-13, 2025. Addressing…
Protein Prediction LG Develops Next-Generation AI for Protein Structure Prediction to Revolutionize Drug Discovery On February 5th, LG AI Research took a significant step in advancing the field of artificial intelligence-driven biotechnology by signing a joint research agreement with Professor…
Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease Fabry Disease Sangamo Therapeutics a genomic medicine company, has announced updated results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec (ST-920), its proprietary gene therapy candidate for Fabry disease.…
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a significant contribution to the field of acute ischemic stroke (AIS)…
Medications from Miist Therapeutics Secures $7M in Funding to Develop Fast-Acting Treatments Medications Miist Therapeutics, a trailblazing company focused on the development of physics-based inhaled medicines, has announced that it has secured $7 million in seed funding from a group…
LEO Pharma Reports Positive DELTA TEEN Results for Anzupgo® in Adolescent CHE LEO Pharma Reports A/S, a global leader in medical dermatology, has announced the successful completion of its DELTA TEEN trial, a pivotal phase 3 clinical study evaluating Anzupgo®…
United Therapeutics Announces Full Enrollment in TETON 1 Study of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis Inhaled Treprostinil United Therapeutics Corporation a public benefit corporation, recently announced the completion of full enrollment in its pivotal TETON 1 clinical study. This…